Symbio Pharmaceuticals Limited (JP:4582)
:4582
Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥90.00
¥6.00(2.96%)
At close: 4:00 PM EST
¥90.00
¥6.00(2.96%)
Day’s Range― - ―
52-Week Range¥71.00 - ¥229.00
Previous CloseN/A
Volume447.50K
Average Volume (3M)577.10K
Market Cap
¥5.41B
Enterprise Value¥3.43B
Total Cash (Recent Filing)¥3.05B
Total Debt (Recent Filing)¥1.30B
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.12
Shares Outstanding76,352,486
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Healthy Gross MarginThe company reports a meaningful gross margin even while overall profitability has deteriorated. Durable gross margin indicates underlying product pricing power and favorable unit economics, which can support recovery in operating profitability if overheads are controlled or sales scale improves.
Specialized Oncology/hematology FocusA focused franchise targeting oncology and hematology concentrates R&D and commercialization in niches with high unmet need. This structural positioning supports sustained pricing, targeted regulatory pathways, and partner interest, making long-term revenue opportunities more durable than broad commodity markets.
In-licensing / Partnership ModelRelying on in-licensing and partner-led commercialization reduces capital intensity and allows access to external pipelines. Upfronts, milestones and royalties provide non-linear revenue potential and scale without full internal R&D burden, a durable business model for specialty biopharma when partner execution succeeds.
Bears Say
Sharp Revenue DeclineA roughly 28% revenue decline in 2025, following prior drops, is a structural concern: persistent top-line erosion reduces scale, undermines fixed-cost coverage and pricing leverage, and impairs the firm's ability to fund trials or commercialization without consistent recovery or new revenue streams.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow through 2023–2025 creates ongoing financing needs. Reliance on external capital elevates dilution or debt risk, constrains discretionary R&D and commercialization investments, and heightens liquidity risk if negative cash generation persists over the medium term.
Rising Leverage And Compressed EquityDebt increased to about ¥2.0B in 2025 from near-zero prior years, pushing debt above equity. Higher leverage reduces financial flexibility, increases interest and covenant risk, and limits capacity to fund licenses or acquisitions without raising capital, a lasting constraint until balance sheet repair occurs.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥71.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥5.41B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Jul 30, 2026 which is in 54 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on May 07, 2026. The company reported -¥35.89 earnings per share for the quarter, missing the consensus estimate of N/A by -¥35.89.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 76,352,486 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥35.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―